Potassium binders
Patiromer and sodium zirconium cyclosilicate for hyperkalaemia.
Key point
In type 2 diabetes with hyperkalemia, sodium zirconium cyclosilicate did not demonstrate noninferiority to potassium-restricted diet for achieving normokalemia.
From: Sodium zirconium cyclosilicate compared with potassium restriction for hyperkalemia management in type 2 diabetes: The SILVERSTAR trial (J Diabetes Investig, 2026 Sep) ↗Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 5, 4, 6, 3, 2.
All papers from the last 12 months
60 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Navigating the data-scarce landscape of pediatric hyperkalemia: a perspective on sodium zirconium cyclosilicatePediatr Nephrol2026 DecPMID 42059926Review
- The Unfulfilled Promise of Potassium Binding in Heart Failure With Reduced Ejection FractionJ Am Coll Cardiol2026 Oct 13PMID 42615956
- Sustained potassium control and recurrent hyperkalemia during individualized potassium-guided sodium zirconium cyclosilicate titration in maintenance hemodialysis: a post hoc analysis of a randomized trialBMC Nephrol2026 Oct 12PMID 42875751RCT
- Ionic immune checkpoint blockade through potassium-scavenging hydrogel to potentiate CD8(+) T cell-mediated cancer immunotherapyBiomaterials2026 OctPMID 41999708
- Overcoming Hyperkalaemia to Optimise Heart Failure Therapy: The Emerging Role of Novel Potassium BindersCard Fail Rev2026PMID 42866084Review
- Letter to the Editor: Enhancing renin-angiotensin-aldosterone system inhibitors utilization through patiromer adherence - real-world insights for nephrology practiceWorld J Nephrol2026 Sep 25PMID 42626019
- Beyond potassium lowering: interpreting an adaptive sodium zirconium cyclosilicate strategy in hemodialysisInt Urol Nephrol2026 Sep 9PMID 42714792
- Sodium zirconium cyclosilicate compared with potassium restriction for hyperkalemia management in type 2 diabetes: The SILVERSTAR trialJ Diabetes Investig2026 SepPMID 42423524RCT
- The Endoscopic Removal of a Gastric Bezoar Made of Sodium Zirconium Cyclosilicate HydrateIntern Med2026 Sep 1PMID 41535045
- Post-marketing safety associated with sodium zirconium cyclosilicate: a pharmacovigilance study based on the FDA reporting systemExpert Opin Drug Saf2026 SepPMID 40151141
More nephrology trends
All specialties →Complement inhibitors in kidney disease
Iptacopan, avacopan and other complement inhibitors in glomerular disease.
Key point: Complement inhibitors had no overall effectiveness or safety advantage over plasma therapy in atypical hemolytic uremic syndrome, except lower relapse rates.
APOL1 kidney disease
Kidney disease linked to APOL1 gene variants.
Home dialysis
Home haemodialysis and peritoneal dialysis.
Key point: Core interventions to reduce PD-related infections focus on surveillance, standardized staff and patient training, infection prevention assessments, and antimicrobial prophylaxis.
HIF-PH inhibitors for anaemia
Oral drugs such as roxadustat for anaemia of kidney disease.
Key point: HIF-PHIs such as roxadustat are reserved for non-dialysis CKD when erythropoiesis-stimulating agents are unsuitable, given potential risks and limited long-term data.
Race-free eGFR
Kidney function equations without a race coefficient.
Pig kidney xenotransplantation
Transplanting genetically modified pig kidneys into humans.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
patiromer[tiab] OR "sodium zirconium cyclosilicate"[tiab]Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.